Skip to main content
. 2024 May 31;42(29):3400–3409. doi: 10.1200/JCO.24.00581

FIG A5.

FIG A5.

Mutational landscape in (A) lorlatinib and (B) crizotinib patients at screening and EOT. None indicates no mutation, which includes no ctDNA samples and failed samples. If all mutations detected are SILENT, the column corresponding to the sample is blank. One crizotinib patient had no screening visit sample and was not included in the plot for screening. EOT, end of treatment; NoRearr, no rearrangement; OthRearr, other rearrangement.